Pilot Randomized Phase II Study of Celecoxib in Oral Premalignant Lesions
暂无分享,去创建一个
S. Lippman | J. Lee | V. Papadimitrakopoulou | A. Dannenberg | F. Ondrey | C. Nathan | D. Peterson | W. William | B. Yueh | J. Boyle | B. Du | J. Helman | A. El-Naggar | Lei Feng | A. Atwell | J. Lee
[1] S. Lippman,et al. The Convergent Development of Molecular-Targeted Drugs for Cancer Treatment and Prevention , 2007, Clinical Cancer Research.
[2] M. Bertagnolli. Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. , 2007, The Lancet. Oncology.
[3] A. Shar,et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. , 2007, Journal of the National Cancer Institute.
[4] J. Baron,et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. , 2006, Gastroenterology.
[5] G. Lodi,et al. Interventions for treating oral leukoplakia. , 2006, The Cochrane database of systematic reviews.
[6] M. Pillai,et al. NF-kappaB and COX-2 during oral tumorigenesis and in assessment of minimal residual disease in surgical margins. , 2006, Experimental and molecular pathology.
[7] S. Solomon,et al. Celecoxib for the prevention of sporadic colorectal adenomas. , 2006, The New England journal of medicine.
[8] S. Solomon,et al. Celecoxib for the prevention of colorectal adenomatous polyps. , 2006, The New England journal of medicine.
[9] G. Mills,et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward , 2006, Clinical Cancer Research.
[10] Edward S. Kim,et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. , 2006, Journal of the National Cancer Institute.
[11] S. Lippman,et al. Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. , 2006, Cancer research.
[12] W. Hong,et al. Focus on head and neck cancer. , 2004, Cancer cell.
[13] J. Boyle. Cyclooxygenase Inhibition as a Target for Prevention of Tobacco-Related Cancers , 2004, Clinical Cancer Research.
[14] S. Steinberg,et al. Randomized, Double-Blind, Placebo-Controlled Phase IIB Trial of the Cyclooxygenase Inhibitor Ketorolac as an Oral Rinse in Oropharyngeal Leukoplakia , 2004, Clinical Cancer Research.
[15] J. Vishwanatha,et al. Deregulated cyclooxygenase-2 expression in oral premalignant tissues. , 2002, Molecular cancer therapeutics.
[16] W. Lam,et al. 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. , 2002, Cancer research.
[17] M. Sporn,et al. Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development: Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia , 2002 .
[18] B. Levin,et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.
[19] N D Le,et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] J. Shah,et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. , 1999, Cancer research.
[21] G. FitzGerald,et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[22] S. Lippman,et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. , 1998, Journal of the National Cancer Institute.
[23] R. DuBois,et al. Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.
[24] K. Seibert,et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. , 1998, Cancer research.
[25] K. Subbaramaiah,et al. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. , 1997, Carcinogenesis.
[26] Bruno C. Hancock,et al. Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.
[27] S. Lippman,et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment , 1996, Nature Medicine.
[28] R. DuBois,et al. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 , 1995, Cell.
[29] M. Kondo,et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. , 1995, Cancer research.
[30] J. Morrow,et al. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. , 1994, The Journal of clinical investigation.
[31] S. Piantadosi,et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.
[32] R. Weber,et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. , 1993, The New England journal of medicine.
[33] L. Marnett. Aspirin and the potential role of prostaglandins in colon cancer. , 1992, Cancer research.
[34] V. Winn,et al. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. , 1991, The Journal of biological chemistry.
[35] B. Varnum,et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. , 1991, The Journal of biological chemistry.
[36] S. Weitzman,et al. Inflammation and cancer: role of phagocyte-generated oxidants in , 2011 .
[37] A. Nishikawa,et al. Inhibitory effects of non-steroidal anti-inflammatory drugs, piroxicam and indomethacin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male ACI/N rats. , 1989, Cancer letters.
[38] W. Hong,et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. , 1986, The New England journal of medicine.
[39] S. Juhn,et al. Prostaglandins in squamous cell carcinoma of the head and neck: A preliminary study , 1985, The Laryngoscope.
[40] M. Gorsky,et al. Oral leukoplakia and malignant transformation. A follow‐up study of 257 patients , 1984, Cancer.
[41] D. Mccormick,et al. Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent. , 1983, British Journal of Cancer.
[42] M. Sporn,et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[43] T. Eling,et al. Xenobiotic metabolism by prostaglandin H synthase. , 1992, Pharmacology & therapeutics.
[44] T. Eling,et al. Prostaglandin H synthase and xenobiotic oxidation. , 1990, Annual review of pharmacology and toxicology.
[45] Y. Konishi,et al. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. , 2001, Cancer research.
[46] V. Steele,et al. Chemoprevention of Colon Carcinogenesis by Sulindac , a Nonsteroidal Anti-inflammatory Agent 1 , 2022 .